![Alexander William Blyth](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alexander William Blyth
Chief Executive Officer at LIfT BioSciences Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Patrick Burgermeister | M | 55 |
LIfT BioSciences Ltd.
![]() LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | - |
Bo Rode Hansen | M | - |
LIfT BioSciences Ltd.
![]() LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | 1 years |
Matt Pierce | M | - |
LIfT BioSciences Ltd.
![]() LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | 5 years |
Marco Gottardis | M | - |
LIfT BioSciences Ltd.
![]() LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | 1 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alexander William Blyth
- Personal Network